ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
June 06, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...